Poly-basic peptides and polymers as new drug candidates against Plasmodium falciparum

Roshan Sivakumar, Katherine Floyd, Jessey Erath, Alex Jacoby, Jenny Kim Kim, Peter O. Bayguinov, James A.J. Fitzpatrick, Dennis Goldfarb, Marko Jovanovic, Abhai Tripathi, Sergej Djuranovic, Slavica Pavlovic-Djuranovic

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Plasmodium falciparum, the malaria-causing parasite, is a leading cause of infection-induced deaths worldwide. The preferred treatment approach is artemisinin-based combination therapy, which couples fast-acting artemisinin derivatives with longer-acting drugs, such as lumefantrine, mefloquine, and amodiaquine. However, the urgency for new treatments has risen due to the parasite's growing resistance to existing therapies. In this study, a common characteristic of the P. falciparum proteome—stretches of poly-lysine residues, such as those found in proteins related to adhesion and pathogenicity—is investigated for its potential to treat infected erythrocytes. Methods: This study utilizes in vitro culturing of intra-erythrocytic P. falciparum to assess the ability of poly-lysine peptides to inhibit the parasite’s growth, measured via flow cytometry of acridine orange-stained infected erythrocytes. The inhibitory effect of many poly-lysine lengths and modifications were tested this way. Affinity pull-downs and mass spectrometry were performed to identify the proteins interacting with these poly-lysines. Results: A single dose of these poly-basic peptides can successfully diminish parasitemia in human erythrocytes in vitro with minimal toxicity. The effectiveness of the treatment correlates with the length of the poly-lysine peptide, with 30 lysine peptides supporting the eradication of erythrocytic parasites within 72 h. PEG-ylation of the poly-lysine peptides or utilizing poly-lysine dendrimers and polymers retains or increases parasite clearance efficiency and bolsters the stability of these potential new therapeutics. Lastly, affinity pull-downs and mass-spectrometry identify P. falciparum’s outer membrane proteins as likely targets for polybasic peptide medications. Conclusion: Since poly-lysine dendrimers are already FDA-approved for drug delivery and this study displays their potency against intraerythrocytic P. falciparum, their adaptation as anti-malarial drugs presents a promising new therapeutic strategy for malaria.

Original languageEnglish (US)
Article number227
JournalMalaria journal
Volume23
Issue number1
DOIs
StatePublished - Dec 2024

ASJC Scopus subject areas

  • Parasitology
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Poly-basic peptides and polymers as new drug candidates against Plasmodium falciparum'. Together they form a unique fingerprint.

Cite this